Search
Migraine Clinical Trials in Portland, OR
A listing of 11 Migraine clinical trials in Portland, OR actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 11 of 11
The city of Portland, Oregon, currently has 11 active clinical trials seeking participants for Migraine research studies.
Featured Trial
Migraine Trials
Recruiting
Migraine trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Migraine
Featured Trial
Child/Teen Migraine
Recruiting
The study is evaluating an investigational product for the treatment of migraine in children the ages of 6 to 17. The investigational product is currently approved to treat migraines in adults.
Conditions:
Migraines
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
Recruiting
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/19/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Migraine
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
Recruiting
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2024
Locations: Providence Health & Services, Portland, Oregon
Conditions: Episodic Migraine
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Recruiting
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Migraine
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Recruiting
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Migraine
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
06/17/2024
Locations: Providence Health & Services, Portland, Oregon
Conditions: Chronic Migraine
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Recruiting
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2024
Locations: Providence Brain & Spine Institute-research coordinator's office, Portland, Oregon +3 locations
Conditions: Pediatric Migraine
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
Recruiting
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine. The study hypothesis is that in pediatric participants with chronic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/12/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Migraine
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Recruiting
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents.
Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and adolescents (a... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/05/2024
Locations: Providence Brain and Spine Institute /ID# 231607, Portland, Oregon
Conditions: Migraine
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Recruiting
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolescents (≥ 6 to < 18 years of age).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
05/31/2024
Locations: Providence Portland Medical Center, Portland, Oregon +3 locations
Conditions: Acute Treatment of Migraine
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
Recruiting
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing chronic migraine.
A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound.
Chronic migraine is defined as having at least 15 days of headache a month with at least 8 of those days being migraine headache day... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: 840044, Portland, Oregon
Conditions: Chronic Migraine
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
Recruiting
A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.
Gender:
All
Ages:
Between 6 years and 11 years
Trial Updated:
02/14/2024
Locations: Upsher-Smith Clinical Trial Site #6, Portland, Oregon
Conditions: Migraine Disorders
1 - 11 of 11